Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Alimera Sciences Inc (NQ: ALIM )

4.710 USD -0.030 (-0.63%)
Official Closing Price Updated: 1:00 PM EST, Nov 27, 2020 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 23,100
Open 4.700
Bid (Size) 4.070 (5)
Ask (Size) 7.000 (9)
Prev. Close 4.740
Today's Range 4.700 - 4.836
52wk Range 2.860 - 9.980
Shares Outstanding 70,038,411
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Alimera Sciences Announces Participation at the 11th Annual Craig-Hallum Alpha Select Conference on Tuesday, November 17, 2020
From GlobeNewswire News Releases
Alimera Sciences Announces Real-World Clinical Data for ILUVIEN® to be Presented at the American Academy of Ophthalmology 2020 Virtual Conference
From GlobeNewswire News Releases

Performance

YTD
-42.28%
-42.28%
1 Month
+10.95%
+10.95%
3 Month
-20.30%
-20.30%
6 Month
-6.36%
-6.36%
1 Year
-31.04%
-31.04%

More News

Read More
Alimera Sciences Announces Third Quarter 2020 Financial Results
From GlobeNewswire News Releases
Alimera Sciences to Report Third Quarter 2020 Financial Results on Wednesday, October 28, 2020 and Provide Corporate Update
From GlobeNewswire News Releases
Alimera Sciences Announces Multiple Posters and Papers Highlighting the Durability of ILUVIEN® To Be Presented at the EURETINA 2020 Virtual Congress
From GlobeNewswire News Releases
Alimera Sciences Signs Distribution Agreement With Medis Pharmaceutical to Commercialize Iluvien® in Austria and the Czech Republic
From GlobeNewswire News Releases
UPDATE -- Alimera Sciences Announces Participation at the H.C. Wainwright 22nd Annual Global Virtual Investment Conference on September 15, 2020
From GlobeNewswire News Releases
Alimera Sciences Announces Participation at the H.C. Wainwright 22nd Annual Global Virtual Investment Conference on September 15, 2020
From GlobeNewswire News Releases
Alimera Sciences Obtains Reimbursement Approval for ILUVIEN® Use in Non-Infectious Posterior Uveitis in Scotland
From GlobeNewswire News Releases
Alimera Sciences Announces Enrollment of First Patient in Landmark NEW DAY Clinical Trial to Evaluate ILUVIEN® as Baseline Therapy for Diabetic Macular Edema
From GlobeNewswire News Releases
Alimera Sciences Announces National Reimbursement Granted for ILUVIEN® in the Netherlands
From GlobeNewswire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.